Our phase I study showed responses to the dual anti-LAG-3/anti-PD-1 therapy in patients with various cancer indications, including confirmed CRs per RECIST V.1.1, in three patients with thymoma, adrenocortical carcinoma, and triple-negative breast cancer, as well as an additional CR by irRC in a patient with cervical cancer. This evidence concerns the gene PDCD1 and cervical carcinoma.